Exhibit 10.16


 





	



 





May 19, 2014


 


PRIVATE AND CONFIDENTIAL


 


Michael “Mike” Lehmann 

2401 Victoria Park Lane 

Raleigh,
NC 27614


 


		RE:	Amendment to Employment Contract



 


Dear Mike:


 


Further to our discussions, this letter (the “Letter”),
effective as of June 9, 2014 (the “Amendment Effective Date”), confirms that Patheon Pharmaceutical Services Inc. (the
“Company”), has agreed to increase your base salary in your current role of President, Global PDS, and has further
agreed to provide you with the equity grant described below. Once signed, this Letter will serve as the first amendment to the
Employment Agreement between you and the Company dated November 1, 2012 (collectively, the “Employment Agreement”).
Any terms used in this Letter that are not defined herein have the definition ascribed to them in the Employment Agreement.


 


For purposes of clarity, please be advised that the Company
is a subsidiary of DPx Holdings B.V. (“DPx”). DPx the corporate parent of a group of businesses engaged in the provision
of commercial manufacturing and development services (pharmaceuticals and fine chemicals), related services, and the development,
manufacture, distribution and marketing of proprietary products. The Company serves as the corporate shared services entity for
DPx and other members of the DPx Group.


 


		1.	General Provisions



 


This Letter, when fully executed, together with the
Employment Agreement, reflects the entire agreement regarding the terms and conditions of your employment and promotion. Unless
expressly modified by this Letter, the terms and conditions of the Employment Agreement, including without limitation your confidentiality,
assignment of inventions, non-solicitation and non-competition undertakings, will remain the same.


 


		2.	Compensation & Benefits



 


		a.	Base Salary: In recognition of your performance, your annual base salary will be increased to $415,000 subject to standard
withholdings and deductions and payable in regular installments in accordance with the Company’s normal payroll practices.



 












	 	 	 	 	 


 




    	 



    	 



    




 


		b.	Equity Incentive Plan:



 


(i)          You
shall be eligible to participate in the JLL/DELTA PATHEON HOLDINGS, L.P. 2014 Equity Incentive Plan (the “MEIP”) and
shall be eligible to be awarded Membership Units from time to time in accordance with the terms of such MEIP, the Membership Unit
award agreement, and all related documents (collectively, the MEIP Related Documents”).


 


(ii)          Subject
to approval of the Board of Directors at a meeting following the Effective Date, you will be awarded four thousand (4,000) of the
Membership Units, which shall be granted subject to the MEIP Related Documents. You will be required to comply with the MEIP Related
Documents, as amended from time to time.


 


3. Other Benefits: All other compensation and
benefits terms (including without limitation, severance terms and post-employment restrictions) shall be as provided in your Employment
Agreement. For purposes of clarity, any changes, modifications, or additions to your compensation and benefits terms require the
review and approval of Patheon’s Compensation and Human Resources Committee (i.e., cannot be approved at the Company level).


 


[SIGNATURE PAGE FOLLOWS]


 
















	 	 	 	 	Page | 2


 








    	 



    	 



    




 


By executing this Letter, you confirm your decision to accept
the amendment to the terms of your Employment Agreement and you agree that your employment will be governed by the Employment
Agreement, as amended by this Letter. 


	 	 
	 	Very truly yours,
	 	 
	 	Patheon Pharmaceutical Services Inc.
	 	 
	 	James C. Mullen 

Chief Executive Officer


 


Read, understood, consented, and agreed as of this 17 day of
June, 2014: 


	 	 	 	 
	SIGNED, SEALED AND DELIVERED

    in the presence of

     


	 	)

                                    )

				    )

                                    )

                                    )

                                    )
	
	Name of Witness:	 	 	Michael Lehmann


 























	 	 	 	 	Page | 3